Evidence map›Paper›PMID 29309831›Full record

ArticleMatrix biology : journal of the International Society for Matrix Biology2018

Mutant cartilage oligomeric matrix protein (COMP) compromises bone integrity, joint function and the balance between adipogenesis and osteogenesis.

Francoise Coustry, Karen L Posey, Tristan Maerz, Kevin Baker, Annie M Abraham, Catherine G Ambrose, Sabah Nobakhti, Sandra J Shefelbine, Xiaohong Bi, Michael Newton and 6 more

Abstract read
In one paragraph

Article in Matrix biology : journal of the International Society for Matrix Biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Long non-coding RNA CASC2 regulates osteoblasts matrix mineralization.Frontiers in bioengineering and biotechnology · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The "other" 15-40%: The Role of Non-Collagenous Extracellular Matrix Proteins and Minor Collagens in Tendon.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2020
    Review
  17. Thrombospondin 1 and Its Diverse Roles as a Regulator of Extracellular Matrix in Fibrotic Disease.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2019
    Review
  18. Article
  19. Cartilage oligomeric matrix protein: COMPopathies and beyond.Matrix biology : journal of the International Society for Matrix Biology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Francoise CoustryMcGovern Medical School, UTHealth, Department of Pediatrics, United States. Electronic address: Francoise.Coustry@uth.tmc.edu.
Karen L PoseyMcGovern Medical School, UTHealth, Department of Pediatrics, United States.
Tristan MaerzUniversity of Michigan, Department of Orthopaedic Surgery and MedSport, United States.
Kevin BakerBeaumont Hospital, Royal Oak Department of Orthopaedic Surgery, United States.
Annie M AbrahamMcGovern Medical School at UTHealth, Department of Orthopedic Surgery, United States.
Catherine G AmbroseMcGovern Medical School at UTHealth, Department of Orthopedic Surgery, United States.
Sabah NobakhtiNortheastern University, Department of Mechanical and Industrial Engineering, United States.
Sandra J ShefelbineNortheastern University, Department of Mechanical and Industrial Engineering, United States.
Xiaohong BiMcGovern Medical School, UTHealth, Institute of Molecular Medicine, United States.
Michael NewtonBeaumont Hospital, Royal Oak Department of Orthopaedic Surgery, United States.
Karissa GawronskiBeaumont Hospital, Royal Oak Department of Orthopaedic Surgery, United States.
Lindsay RemerBeaumont Hospital, Royal Oak Department of Orthopaedic Surgery, United States.
Alka C VeerisettyMcGovern Medical School, UTHealth, Department of Pediatrics, United States.
Mohammad G HossainMcGovern Medical School, UTHealth, Department of Pediatrics, United States.
Frankie ChiuMcGovern Medical School, UTHealth, Department of Pediatrics, United States.
Jacqueline T HechtMcGovern Medical School, UTHealth, Department of Pediatrics, United States; UTHealth School of Dentistry, United States.
The University of Texas Health Science Center at Houston · USBeaumont Hospital, Royal Oak · USNortheastern University · USThe University of Texas Health Science Center · USUniversity of Michigan · USUniversity of Texas Health Science Center at Dallas · US

Funding

Consequences of Mutant COMP Expression and Therapeutic Approaches in Transgenic MiceR01AR057117 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HECHT, JACQUELINE T, POSEY, KAREN LASHEA · 2010 to 2020
$4.2M
NIAMS NIH HHS R01 AR057117
6 · The paper itself

Abstract

Mutations in COMP (cartilage oligomeric matrix protein) cause severe long bone shortening in mice and humans. Previously, we showed that massive accumulation of misfolded COMP in the ER of growth plate chondrocytes in our MT-COMP mouse model of pseudoachondroplasia (PSACH) causes premature chondrocyte death and loss of linear growth. Premature chondrocyte death results from activation of oxidative stress and inflammation through the CHOP-ER pathway and is reduced by removing CHOP or by anti-inflammatory or antioxidant therapies. Although the mutant COMP chondrocyte pathologic mechanism is now recognized, the effect of mutant COMP on bone quality and joint health (laxity) is largely unknown. Applying multiple analytic approaches, we describe a novel mechanism by which the deleterious consequences of mutant COMP retention results in upregulation of miR-223 disturbing the adipogenesis - osteogenesis balance. This results in reduction in bone mineral density, bone quality, mechanical strength and subchondral bone thickness. These, in addition to abnormal patterns of ossification at the ends of the femoral bones likely contribute to precocious osteoarthritis (OA) of the hips and knees in the MT-COMP mouse and PSACH. Moreover, joint laxity is compromised by abnormally thin ligaments. Altogether, these novel findings align with the PSACH phenotype of delayed ossification and bone age, extreme joint laxity and joint erosion, and extend our understanding of the underlying processes that affect bone in PSACH. These results introduce a novel finding that miR-223 is involved in the ossification defect in MT-COMP mice making it a therapeutic target.

Indexed as

MutationAchondroplasiaAdipogenesisAnimalsBone DensityCartilage Oligomeric Matrix ProteinDisease Models, AnimalHumansMiceMicroRNAsOsteogenesisUp-RegulationCartilage Oligomeric Matrix ProteinComp protein, mouseMicroRNAsMIRN223 microRNA, mouseAdipogenesisBone architectureCartilageCartilage oligomeric matrix proteinmiR-223OsteogenesisPseudoachondroplasia

Identifiers

PMID29309831
PMCPMC5910205
OpenAlexW2781623025

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.